Biosimilar insulins: a European perspective

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|5|445-451

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.5, 2015-05, pp. : 445-451

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biosimilar insulins: guidance for data interpretation by clinicians and users

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 911-918

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biosimilar insulins: guidance for data interpretation by clinicians and users

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 911-918

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. S3, 2015-03 ,pp. : S123-S132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biosimilar: what it is not

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 5, 2015-11 ,pp. : 949-956

John Wiley & Sons Inc

Access to resources Recommend Favorite

GP specialty training: a European perspective

By Olesen Frede   Maagaard Roar  

British Journal of General Practice, Vol. 57, Iss. 545, 2007-12 ,pp. : 940-941

Royal College of General Practitioners

Access to resources Recommend Favorite